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Abstract
Bacterial biofilms play an important role in the persistent colonization of the respiratory tract in cystic fibrosis (CF) patients. The trade-
offs among planktonic or sessile modes of growth, mutation frequency, antibiotic susceptibility and mutant prevention concentrations
(MPCs) were studied in a well-defined collection of 42 CF Pseudomonas aeruginosa isolates. MICs of ciprofloxacin, tobramycin, imipenem
and ceftazidime increased in the biofilm mode of growth, but not the MPCs of the same drugs. The mutation frequency median was sig-
nificantly higher in planktonic conditions (1.1 · 10)8) than in biofilm (9.9 · 10)9) (p 0.015). Isolates categorized as hypomutable
increased their mutation frequency from 3.6 · 10)9 in the planktonic mode to 6 · 10)8 in biofilm, whereas normomutators (from
9.4 · 10)8 to 5.3 · 10)8) and hypermutators (from 1.6 · 10)6 to 7.7 · 10)7) decreased their mutation frequencies in biofilm. High and
low mutation frequencies in planktonic growth converge into the normomutable category in the biofilm mode of growth of CF P. aeru-
ginosa, leading to stabilization of MPCs. This result suggests that once the biofilm mode of growth has been established, the propensity
of CF P. aeruginosa populations to evolve towards resistance is not necessarily increased.
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Introduction
Biofilms are complex and organized bacterial communities
that are able to grow in association with different biological
or inert surfaces. The clinical consequences of the biofilm
mode of growth of pathogenic bacteria relate to the difficulty
of therapeutic eradication of sessile cells forming such supra-
cellular structures [1,2]. Bacterial biofilms play an important
role in the persistent colonization of the respiratory tract in
cystic fibrosis (CF) patients, and have been associated with a
significant increase in antibiotic resistance [3–6]. Another
important feature of CF pathogens is hypermutability, a phe-
nomenon that confers a selective advantage, as the bacteria
are often exposed to a high level of immune response and
high doses of antibiotics for prolonged periods [7,8]. Hyper-
mutable Pseudomonas aeruginosa isolates are frequently
recovered from the lungs of CF patients [7]. More recently,
it has been shown that the biofilm mode of growth might
increase the mutation frequency of the reference strain
P. aeruginosa PAO1, although this possibility has not yet been
explored with clinical isolates [9].
On the other hand, the mutant prevention concentration
(MPC) is the lowest antibiotic concentration that inhibits the
growth of single resistant mutants emerging within a high-
density bacterial population. The MPC estimates the ability
of each antibiotic to select resistant mutants, and cannot be
predicted from the MIC [10,11]. By comparison of MPCs
and MICs, a mutant selection window can be defined, show-
ing a range of concentrations at which resistant mutants
emerged. This concept has clinical applications in CF [12,13].
Theoretically, the selection window is expected to be wider
in hypermutable isolates, as the diversity of mutants (particu-
larly for double mutants) is larger. The aim of this work was
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to explore the possible differences in mutation frequency of
cells with planktonic and biofilm modes of growth in a col-
lection of CF P. aeruginosa isolates and their influence on
MPCs.
Materials and Methods
Bacterial isolates
Forty-two P. aeruginosa clinical isolates from sputum samples
of ten patients from our CF Unit (2002–2006) were studied
(two to nine isolates per patient). Selection of isolates was
carried out in order to ensure a collection representing CF
isolates with the following criteria: (i) different pulsotype; (ii)
different colonial morphotype; (iii) different year of isolation,
if belonging to a particular patient; and (iv) as far as possible,
representing each one of the three mutation frequency cate-
gories in the planktonic mode of growth. Genetic diversity
was determined by pulsed-field gel electrophoresis (PFGE)–
XbaI and UPGMA dendrogram construction (Phoretrix 5.0
software; Bio-Rad, Hercules, CA, USA). Relationship among
the isolates was considered when the Dice coefficient was
‡0.7.
Mutation frequency determination
Independent triplicate 10-mL overnight Mueller–Hinton
broth (Difco, Detroit, MI, USA) cultures of each P. aeruginosa
isolate were centrifuged and resuspended in 1 mL of of sal-
ine solution to ensure a number of cells exceeding 109 CFU/
mL. Serial ten-fold dilutions were plated in LB agar (Difco)
to determine the number of viable cells, and 0.5 mL was
seeded into LB agar plates with 300 mg/L rifampicin. Plates
were incubated (48 h), and the total number of mutant colo-
nies was determined. The mutation frequency was defined as
the median number of colonies of mutants divided by the
median number of total viable cells obtained in the different
tubes. If discordance between median and mean values was
high, cultures were replicated in triplicate [14]. Isolates were
classified as hypomutators (f-range: 5 · 10)10 to 5 · 10)9),
normomutators (7.5 · 10)9 to 7.5 · 10)8), and hypermuta-
tors (1 · 10)7 to 5 · 10)6), as previously defined [15].
Mutation frequencies for biofilm formation were determined
similarly, but using bacterial cells from nitrocellulose mature
biofilms as the incoculum [16]. This method was used to
ensure an equivalent inoculum to the planktonic conditions
(at least 109 CFU/mL). In short, biofilm was developed for
3 days at 37C on a nitrocellulose filter disk inoculated with
100 lL of an overnight LB broth culture of known planktonic
mutation frequency, and placed on an LB agar plate. The bac-
teria growing on the filter surface (biofilm bacteria) were
suspended in saline solution, homogenized with vortexing,
and plated in the LB agar plates containing rifampicin
(300 mg/L). The efficiency of vortex homogenization was
ascertained by light microscopy (less than one bacterial
clump per ·1000 optical field). The density of viable cells
was calculated with the use of ten-fold dilutions; only bio-
films with an initial concentration of 109–1010 CFU/mL were
considered. The P. aeruginosa PAO1 normomutator strain
and the hypermutator PAO1DmutS derivative were used as
controls [17].
Antibiotic susceptibility testing
Susceptibility to ciprofloxacin, tobramycin, imipenem and
ceftazidime was determined by standard microdilution [18].
P. aeruginosa ATCC 27853 was used as the control strain in
each run. Breakpoint susceptibility criteria are given in
Table 1 [19]. The biofilm MIC susceptibility assay was per-
formed using a flat-bottomed 96-well microtitre plate (cata-
log no. 269787; Nalgene Nunc International, Rochester, NY,
USA). Bacterial biofilms were formed by immersing the
pegs of a modified polystyrene microtitre lid (catalog
no. 445497; Nunc TSP system) into this biofilm growth
plate. Peg lids were rinsed three times in sterile water,
placed onto flat-bottomed microtitre plates containing two-
fold dilutions of antibiotic, and incubated for 18–20 h at
37C [20].
MPC
For MPCs in the planktonic mode of growth, 0.5 mL of an
overnight shaking culture in 10 mL of LB broth containing
109–1010 CFU/mL were seeded in LB agar plates supple-
mented with serial dilutions of antibiotics. Plates were incu-
bated at 37C for 48 h, and the MPC corresponded to the
lowest concentration with non-visible growth. The Mosko-
witz method [20] was unsuitable for determining the MPC in
mature biofilm, as this technique does not guarantee the
heavy inoculum required. Consequently, biofilms were
formed in nitrocellulose filters deposited over LB agar plates
[16]. After 3 days of incubation at 37C, all of the bacteria
on the filter were suspended in 3 mL of saline. Under these
conditions, the cell density was comparable to that of plank-
tonic growth (109–1010 CFU/mL), and 0.5 mL of the suspen-
sion was seeded in antibiotic-supplemented plates as
described above. Both media and incubation conditions were
identical for planktonic growth and biofilm, but the inoculum
was different: for planktonic growth, a 24-h 10-mL LB broth
inoculum was used, whereas for biofilm, 3 days of mature
growth in a nitrocellulose disk was used. This difference was
attributable to the high cell density required for the MPC
determination.
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Statistical analysis
All data were obtained from triplicates of separate experi-
ments. Continuous data were expressed as means and stan-
dard deviations; categorical data were expressed as relative
and absolute frequencies, and median values were used for
them. To investigate whether the differences in mutation fre-
quencies between biofilm and planktonic growth were asso-
ciated with baseline frequency of mutation, a linear
regression analysis was used, with the logarithm of the differ-
ence in mutation rate between biofilm and planktonic growth
as a dependent variable and the (baseline) frequency of muta-
tion as an independent variable. Paired comparisons of MIC
and MPC distributions between the different types of growth
(biofilm and planktonic) were performed (Wilcoxon signed
rank sum test). Classes of mutation frequency (hypomuta-
tors, normomutators or hypermutators) were also com-
pared (Kruskall–Wallis test). The significance level was 0.05.
For multiple post hoc pairwise comparisons, a Bonferroni
corrected significance level was used (a = 0.016).
Results
Genetic and phenotypic diversity of P. aeruginosa isolates
Forty of the 42 CF P. aeruginosa isolates were clustered in
18 PFGE patterns or pulsotypes (A–R), and two isolates
(21 and 36) were consistently untypeable (Fig. 1). Morpho-
types were determined on Columbia agar with 5% sheep
blood, and were as follows: mucoid (23 isolates, 55%),
enterobacterial (seven isolates, 17%), dwarf (five isolates,
12%), metallic (four isolates, 9%) and rough (three isolates,
7%).
Mutation frequency in planktonic and biofilm conditions
Rifampicin mutation frequencies (f) in planktonic conditions
allowed us to classify our 42 isolates as hypomutators (13 iso-
lates, 31%) normomutators (21 isolates, 50%) and hypermuta-
tors (eight isolates, 19%). Similar distributions of PFGE
patterns and morphotypes were observed in all three catego-
ries (Fig. 1). When biofilm conditions were applied, 18 isolates
were hypomutators (43%), 13 were normomutators (31%)
and 11 were hypermutators (26%) (Figs 1 and 2). A detailed
distribution of frequencies of mutation per isolate, in plank-
tonic or biofilm conditions, is shown in Fig. 3. Linear regres-
sion analysis, based on the difference in logarithm mutation
frequency values between planktonic and biofilm growth for
each strain, showed that the overall mutation frequency of all
42 isolates growing in biofilm was significantly lower than in
planktonic mode (p 0.015). The Wilcoxon test also detected
significant differences depending on the initial (planktonic)
class of mutation frequency (hypomutators, normomutators
or hypermutators). As shown in Fig. 3d, hypomutatable iso-
lates had negative results in the planktonic minus biofilm val-
ues, whereas for normomutable and hypermutable isolates,
this difference was always positive. Therefore, isolates that
were hypomutable in planktonic conditions significantly
increased their mutation frequency values in biofilm. In con-
trast, normomutable and hypermutable isolates tended to
reduce their mutation frequency in biofilm (Figs 2 and 3).
Mutation frequencies in planktonic and biofilm conditions
TABLE 1. MIC and mutant prevention concentration (MPC) distribution for the 42 Pseudomonas aeruginosa isolates, and over-
all susceptibility rates in both planktonic and biofilm conditions
Antibiotic dilution (mg/L)
Value50 Value90 % S % R0.25 0.5 1 2 4 8 16 32 64 128 256 512 1024
Ciprofloxacin £1 mg/La ‡4 mg/Lb
MIC 1 2 11 9 8 9 2 2 8 33.3 45.2
MIC in biofilm 1 3 9 8 10 11 12 1 4 16 11.1 69.0
MPC 2 6 9 12 12 1 16 32
MPC in biofilm 15 10 9 7 1 8 32
Tobramycin £4 mg/La ‡16 mg/Lb
MIC 6 6 10 14 2 4 4 16 52.3
MIC in biofilm 2 1 4 10 8 7 2 4 2 2 8 64 40.5 14.3
MPC 4 13 8 13 4 32 64 40.5
MPC in biofilm 5 5 12 8 11 1 32 128
Imipenem £4 mg/La ‡16 mg/Lb
MIC 1 10 5 11 7 5 3 8 32 38.1 35.7
MIC in biofilm 4 5 5 10 11 5 2 32 128 9.5 78.6
MPC 2 9 21 9 1 64 128
MPC in biofilm 13 15 6 5 3 64 256
Ceftazidime £8 mg/La ‡32 mg/Lb
MIC 4 10 10 8 2 4 1 3 16 128 33.3 42.8
MIC in biofilm 2 2 2 5 2 1 1 7 9 11 128 1024 14.3 73.8
MPC 1 2 4 4 9 22 1024 1024
MPC in biofilm 3 3 8 5 17 6 512 1024
R, resistant; S, susceptible. a and b: susceptability and resistant criteria, respectively [19].
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were 2.5 · 10)8 and 7.9 · 10)9 for the PAO1strain, respec-
tively, and 1 · 10)6 and 8 · 10)7 for the PAO1DmutSstrain,
respectively (Fig. 3). Data were also analysed considering the
morphotypes and pulsotypes but differences were not found.
MICs in planktonic and biofilm conditions
Consistently lower antibiotic resistance rates were detected
among the isolates in planktonic conditions than in biofilm
conditions: ciprofloxacin, 45% vs. 69%, p 0.001; tobramycin,
14% vs. 40%, p 0.01; imipenem, 36% vs. 79%, p 0.001; and
ceftazidime, 43% vs. 74%, p 0.001) (Table 1; Fig. 4). Overall
median MICs increased in biofilm conditions for ciprofloxacin
(·3), imipenem (·4), tobramycin (·1.3) and ceftazidime
(·16). Isolates showing a hypermutator phenotype in plank-
tonic conditions had median MICs that were not significantly
higher than those of isolates categorized as normomutable
and hypomutable in the same planktonic conditions. The
increase in MICs from planktonic to biofilm conditions was
less pronounced in hypomutable and normomutable isolates
(Fig. 4). In the PAO1 control strain, the biofilm mode
of growth increased ceftazidime and imipenem MICs (>4);
the increase was less pronounced for ciprofloxacin and
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tobramycin (£4) (Table 2). Almost identical values were
obtained for PAO1DmutS.
MPCs in planktonic and biofilm conditions
Considering all isolates, MPC90s in planktonic/biofilm condi-
tions were: ciprofloxacin, 32/32 mg/L; tobramycin, 64/
128 mg/L; imipenem, 128/256 mg/L; and ceftazidime 1024/
1024 mg/L. This suggests that biofilm formation does not
influence, or eventually only marginally increases, MPCs
(Table 1). Statistical differences were not found, although a
trend towards lower MPCs in biofilm was observed for
ciprofloxacin and ceftazidime, whereas for tobramycin and
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imipenem, MPCs were almost identical to those of plank-
tonic conditions (data not show). For the control PAO1 and
PAO1DmutS strains, these values were 8/4 mg/L for cipro-
floxacin, 128/64 mg/L for tobramycin, 32/64 mg/L for imipe-
nem and 32/‡1024 mg/L for ceftazidime, again suggesting a
low effect of biofilm growth on MPCs, except in the case of
ceftazidime (Table 2). MPCs were not statistically different
for the hypomutable, normomutable and hypermutable iso-
lates.
Discussion
A biofilm mode of growth, hypermutability and the coexis-
tence of different colonial morphotypes characterize P. aeru-
ginosa isolates from CF patients [7,21,22]. Much less is
known about the consequences of the interactions among
these biological traits, particularly concerning on antibiotic
susceptibility. In this work, we explored the potential differ-
ences in mutation frequencies, MICs and MPCs in a collec-
tion of P. aeruginosa isolates from CF patients under
planktonic and sessile growth conditions.
According to conventional knowledge, bacteria in biofilms
(predominantly in stationary phase) should be in a state of
transient genetic instability in relation to the RpoS-dependent
stress response, thus increasing mutation frequencies [23].
Previous observations in our laboratory indicate that hyper-
mutation might increase the spontaneous availability of
mutants of P. aeruginosa, so that if MICs are determined after
the bacteria have been in antibiotic-containing broth for
more than 24 h, mutants might be selected, giving a false
image of resistance in an otherwise predominantly suscepti-
ble population [24]. Hypermutators might produce a further
increase in the number of mutations able to potentially pro-
vide antibiotic resistance, and consequently the concentra-
tion preventing the selection of resistant mutants (the MPC).
Our results suggest that this is not necessarily the case, par-
ticularly when different growth conditions are considered.
Considering all studied isolates, the mutation frequencies
with regard to rifampicin in planktonic conditions were sig-
nificantly higher than those obtained in biofilm. However,
isolates classified as hypomutators under planktonic condi-
tions showed a significant increase in their mutation fre-
quency in the sessile mode of growth (p £0.015), and most
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TABLE 2. MIC and mutant prevention concentration (MPC)
values for the control Pseudomonas aeruginosa isolates
Antibiotic
Control
strain
MIC (mg/L) MPC (mg/L)
Planktonic Biofilm Planktonic Biofilm
Ciprofloxacin PAO1 0.25 0.25 8 4
PAO1DmutS 0.25 0.5 16 4
Tobramycin PAO1 1 4 128 64
PAO1DmutS 4 16 128 64
Imipenem PAO1 4 128 32 64
PAO1DmutS 4 128 32 64
Ceftazidime PAO1 2 ‡1024 32 ‡1024
PAO1DmutS 8 ‡1024 128 ‡1024
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behaved as normomutators. In contrast, isolates grouped as
hypermutators in planktonic conditions tended to decrease
their mutation frequency and also converted to the normo-
mutator category. To our knowledge, this is the first time
that a consistent decrease in mutation frequencies associated
with biofilm formation has been observed. Our results also
indicate that, at least under our experimental conditions, the
stationary mode of growth of CF P. aeruginosa isolates,
resembling that of biofilms, does not result in a higher num-
ber of mutants. This effect was less obvious, but might be
present, in laboratory control strains. Driffield et al. docu-
mented an increase in the rifampicin and ciprofloxacin muta-
tion frequency of the PAO1 strain in biofilms [8]. These
authors used a biofilm formed on a modified Sorbarod appa-
ratus, whereas we used a nitrocellulose filter to obtain ade-
quate stationary inocula for the experimental conditions
[16]. In our study, with a more homogeneous cell suspension
and with a different rifampicin concentration (300 mg/L vs.
4 · MIC) [8], we were unable to observe significant
increases in mutation frequencies for the PAO1 strain.
Numerous studies have focused on antimicrobial suscepti-
bility differences between the planktonic and biofilm modes
of growth, demonstrating that isolates are more resistant in
biofilms, with the exception of macrolides [25–27]. Our
study also showed higher resistance rates in biofilms than in
planktonic conditions, but the overall increase in MICs was
not substantially higher for hypermutable isolates, and this
cannot be explained by higher basal MICs. The results
obtained in this study concerning the shift in mutation fre-
quencies related to mode of growth might provide the rea-
son for this observation, because, in biofilm, there is a
convergence of both hypermutable and hypomutable isolates
towards normomutable phenotypes (Fig. 4). These results
were initially misleading, as the observed increase in MICs
in biofilms was not higher, as would be expected, for the
hypermutable organisms [7]. This was because, a proportion
of hypermutable isolates tend to present a normomutable
phenotype in biofilm. Planktonic hypermutable isolates do
not have increased MICs in biofilm. Only isolates that main-
tain the hypermutable phenotype in biofilm have increased
MICs.
The main caveats regarding our study are based on the
use of mutation frequencies (instead of mutation rates),
potential biases related to the biofilm model, and different
incubation times for planktonic and biofilm inocula. More-
over, differences in growth phase might influence the muta-
tion frequencies. We used 3 days of culture in stationary
phase, which probably results in a different population struc-
ture than overnight cultures. However, our collection
ensures that the different mutation frequency phenotypes
were represented. The reason why there is a possible
decrease in mutation frequencies in biofilm is debatable. Our
results suggest that there might be an excessive cost of har-
bouring particular resistance mutations in biofilm, and this
cost tends to be higher in hypermutable isolates. The classic
observation of greater antibiotic susceptibility in P. aeruginosa
mucoid colonies (which are more prone to form biofilms)
partially supports this statement [28]. Biofilm in CF does not
necessarily increase the development of inheritable antibiotic
resistance, and hypermutation and high-level resistance
evolve more frequently among planktonic bacteria, as a
result of their susceptibility to antimicrobial agents. Accord-
ingly, MPCs were stable in biofilm. This observation suggests
that once MPCs have been exceeded, overdosage of antibiot-
ics during therapy of CF patients is not necessarily required.
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